In 6 HER2-mutant patient derived xenograft models for colorectal, NSCLC, gallbladder and gastric cancers tucatinib and trastuzumab demonstrated promising synergistic antitumor effects in those harboring L755S, V77L or S310Y mutations.63 The gene discussed is ERBB2; the disease is gastric cancer.